Trial Profile
Phase II study of low dose decitabine (5-aza-deoxycytidine) with interferon alfa-2b in advanced renal cell carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Interferon alpha-2b (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 20 Jan 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Jan 2010 Planned end date changed from 1 Oct 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
- 30 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.